BRISBANE, Calif. April 2, 2008 - Cutera, Inc. (Nasdaq: CUTR), a leading provider of laser and other light-based aesthetic systems for practitioners worldwide, is presenting a new fractional ablative technology designed for the treatment of wrinkles at the American Society for Laser Medicine & Surgery Conference (ASLMS) in Kissimmee, Florida, April 2 – 6, 2008.
In 2007, Cutera introduced its proprietary 2790 nm YSGG technology with the Pearl laser for epidermal treatments to improve fine lines, texture and pigment. Cutera’s new device targets the deeper dermal layer with the objective of improving wrinkles. This is the logical next step in the evolution of YSGG in this emerging and growing fractional ablative market.
E. Victor Ross, MD, who performed the initial clinical studies with Pearl, comments, "My confidence in the 2790 nm YSGG wavelength for treating epidermal photo-aging conditions has evolved over the past 18 months. The hybrid mechanism of ablation and coagulation is a characteristic of the 2790 nm wavelength. Using this wavelength, Cutera's latest device will have the ability to create micro-wounds targeting the dermal layer. The skin's response to these wounds should result in the improvement of wrinkles."
"Cutera’s Pearl device has allowed me to effectively treat pigment, texture and fine lines, while renewing the entire skin’s surface," said David J. Goldberg, MD. "With the combination of Pearl and fractional ablative YSGG, we are able to not only treat the entire epidermis, but expect to also stimulate collagen in the deep dermis to address wrinkles. This dual approach has the potential to provide an ideal solution to meet the various needs of my patients."
The device is pending FDA clearance and should be available in the second half of the year on Cutera’s multi-application Xeo platform, as an upgrade to existing customers, and as a standalone unit. A demonstration system will be on display in Cutera’s booth # 603 in the ASLMS exhibit hall.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other light-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning Cutera's ability to develop and manufacture a new, effective product, obtain regulatory approval and successfully market and sell it worldwide to both its installed base and new customers are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. Potential risks and uncertainties that could affect Cutera's business and cause its financial results to differ materially from those contained in the forward-looking statements include its ability to improve sales productivity and performance worldwide; its ability to successfully develop and acquire new products and applications and market them to both its installed base and new customers; unforeseen events and circumstances relating to its operations; government regulatory actions; general economic conditions; and those other factors described in the section entitled, “Risk Factors,” in its most recent Form 10-K as filed with the Securities and Exchange Commission on March 13, 2008. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.